Pro Dex INC

Pro-Dex, Inc. has published an updated investor presentation to be utilized for analyst and investor communications throughout the remainder of 2026.

Pro-Dex, Inc. achieved record quarterly revenue of $19.9 million for Q3 2026, driven by strong orthopedic handpiece shipments.

Pro-Dex, Inc. announced a base salary increase for its Chief Financial Officer, Alisha K. Charlton, to $257,000 per year.

Pro-Dex, Inc. completed the acquisition of Advanced Precision Machining LLC for $8.65 million, funded by cash and a new $6.65 million term loan, extending its manufacturing capabilities and market reach.

Pro-Dex, Inc. announced robust financial results for its fiscal 2026 second quarter and six months, driven by increased sales of its next-generation orthopedic handpiece and strategic customer contract extensions.

Pro-Dex, Inc. announced a three-year contract extension with its largest customer, ensuring continued revenue, alongside a $225,000 bonus for CEO Richard L. Van Kirk.

Pro-Dex, Inc. reported significantly increased net income and cash flow for the second quarter and first half of fiscal 2026, driven by the sale of its Monogram Technologies investment and robust orthopedic product sales.

Pro-Dex, Inc. reported a significant increase in net sales and net income for the first quarter of fiscal 2026, driven by strong orthopedic medical device sales and an unrealized gain on investments.

Pro-Dex Inc. announces increased net sales and profitability for the third quarter of fiscal year 2025, driven by growth in medical device sales and repair revenue.

Pro-Dex Inc. announces increased revenue and profitability for Q2 2025, primarily driven by strong growth in orthopedic medical device sales.

Pro-Dex Inc. reports a significant increase in revenue and profitability for the first quarter of fiscal year 2025, primarily driven by strong medical device sales.

Pro-Dex Inc. saw a revenue increase in Q3 2024 compared to the same period last year, but experienced a decrease in net income due to various factors including unrealized losses on investments.

Pro-Dex, Inc. announced a 322% surge in net income and a 155% increase in backlog for fiscal year 2025, driven by strong medical device sales and the launch of a next-generation product.

Pro-Dex, Inc. saw a 17% increase in revenue for fiscal year 2024, driven by growth in medical device sales and repairs, despite a significant decrease in backlog.

Angelita Rebamontan Domingo, a Director of Pro Dex Inc, received 19 shares of common stock on July 23, 2026.

Angelita Rebamontan Domingo, a Director of Pro Dex Inc, sold 998 shares of common stock on March 16, 2026 for $47.24 per share.

Pro-Dex Inc. reports that Chief Financial Officer Alisha Charlton acquired 10,800 shares of common stock on July 1, 2026, under a performance award agreement.

Pro-Dex Inc. director Angelita Rebamontan Domingo reports transactions involving common stock, including shares issued under a performance award and shares withheld for tax obligations.

Pro-Dex Inc. reports on beneficial ownership changes for CEO Richard Van Kirk, detailing stock awards and tax withholdings.

Pro-Dex Inc. CEO Richard Van Kirk Jr. reported the sale of company stock totaling over 8,000 shares through a pre-arranged trading plan.

PRO-DEX, INC. has filed definitive additional materials related to its Schedule 14A proxy statement.

Pro-Dex, Inc. announced its tenth consecutive year of sales growth, reaching $65 million in Fiscal 2025, and outlined proposals for its upcoming annual shareholder meeting.

Pro-Dex, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Pro-Dex, Inc. announces its annual shareholder meeting and highlights a record year with $53 million in sales and expansion plans.

Nicholas J. Swenson and the AO Partners Group have increased their beneficial ownership in Pro-Dex, Inc. to 31.88%.

A group led by Nicholas J. Swenson has increased its beneficial ownership in Pro-Dex Inc. to 31.2%, stating the company's common stock is undervalued and expressing intent to influence policies to maximize shareholder value.

Farnam Street Partners and its affiliates have filed an amended Schedule 13D, revealing a reduced beneficial ownership of Pro-Dex Inc. common stock to 8.6% following a series of open market sales.

Farnam Street Partners and its affiliates, collectively known as the Farnam Group, have filed an Amendment No. 12 to their Schedule 13D, disclosing a reduction in their beneficial ownership of Pro-Dex Inc. common stock to 9.8% following a series of open market sales in January 2025.